問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Hematology & Oncology

Division of Thoracic Medicine

Division of General Internal Medicine

National Taiwan University Cancer Center (在職)

Division of Hematology & Oncology

Division of General Internal Medicine

Division of General Internal Medicine

National Taiwan University Hospital

Division of Hematology & Oncology

更新時間：2023-09-19

吳尚俊
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

208Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

吳尚俊

List

266Cases

2024-01-01 - 2040-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2020-02-01 - 2026-12-31

Phase III

Active
A Phase III, Randomized, Double-Blinded, Placebo-Controlled Study of Tiragolumab, an Anti-Tigit Antibody, in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer

  • Condition/Disease

    Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer

  • Test Drug

    TIRAGOLUMAB、ATEZOLIZUMAB

Participate Sites
8Sites

Recruiting5Sites

Terminated3Sites

2020-01-01 - 2026-12-31

Phase III

Active
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab (Anti-Tigit Antibody) in Patients With Untreated Extensive-Stage Small Cell Lung Cancer

  • Condition/Disease

    Untreated Extensive-Stage Small Cell Lung Cancer

  • Test Drug

    TIRAGOLUMAB、ATEZOLIZUMAB、CARBOPLATIN、ETOPOSIDE

Participate Sites
5Sites

Recruiting3Sites

Terminated2Sites

2020-10-01 - 2027-12-31

Phase III

Active
A Phase III, Open-Label, Randomized Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Patients With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer Who Have Not Progressed After Concurrent Platinum-Based Chemoradiation

  • Condition/Disease

    Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer Who Have Not Progressed After Concurrent Platinum-Based Chemoradiation

  • Test Drug

    ATEZOLIZUMAB, TIRAGOLUMAB

Participate Sites
3Sites

Not yet recruiting1Sites

Recruiting2Sites

2025-08-01 - 2031-12-31

Phase III

Active
A PHASE III, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARASIB AND PEMBROLIZUMAB VERSUS PEMBROLIZUMAB AND PEMETREXED AND CARBOPLATIN OR CISPLATIN IN PATIENTS WITH PREVIOUSLY UNTREATED, KRAS G12C-MUTATED, ADVANCED OR METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER

  • Condition/Disease

    NON−SMALL CELL LUNG CANCER

  • Test Drug

    Injection

Participate Sites
7Sites

Recruiting7Sites

2023-03-01 - 2027-12-31

Phase I/II

Active
A Phase Ib/II, Open-Label, Multicenter Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib in Combination With Other Anti-Cancer Therapies in Patients With Previously Untreated Advanced Or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation

  • Condition/Disease

    Non-Small Cell Lung Cancer

  • Test Drug

    RO7435846(GDC-6036)Pembrolizumab

Participate Sites
4Sites

Not yet recruiting3Sites

Recruiting1Sites

2018-12-01 - 2027-12-31

Phase II/III

Active
A Phase II/III Multicenter Study Evaluating the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Somatic Mutations Detected in Blood (B-FAST: Blood-First Assay Screening Trial)

  • Condition/Disease

    Non-Small Cell Lung Cancer

  • Test Drug

    Tencentriq、Carboplatin-GRY、Cisplatin NeoCorp、Gitrabin、Alimta、Entrectinib、Cotellic、Zelboraf

Participate Sites
7Sites

Recruiting7Sites

楊政達
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

羅永鴻
Taipei Veterans General Hospital

Division of Thoracic Medicine

2024-06-01 - 2030-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting6Sites

2018-04-02 - 2023-12-06

Phase II

Completed
An Open-Label, Multicenter, Phase II Study to Evaluate the Therapeutic Activity of Simlukafusp Alfa (RO6874281), an Immunocytokine, Consisting of Interleukin-2 Variant (IL-2v) Targeting Fibroblast Activation Protein-Α (FAP), in Combination With Atezolizumab (Anti-PD-L1), Administered Intravenously, in Participants With Advanced and/or Metastatic Solid Tumors

  • Condition/Disease

    Advanced and/or Metastatic Solid Tumors

  • Test Drug

    RO6874281、ATEZOLIZUMAB

Participate Sites
2Sites

Terminated2Sites

2020-07-01 - 2022-05-01

Phase I/II

Completed
A Phase 1, Open-label, Multicenter, Safety Study of SAR442720 in Combination With Pembrolizumab in Patients With Advanced Malignancies

  • Condition/Disease

    Advanced Malignancies

  • Test Drug

    SAR442720

Participate Sites
2Sites

Recruiting2Sites

1 2 3 4 5 27
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB